ATE161192T1 - Verfahren zur behandlung einer durch lfa-1 vermittelten störung - Google Patents

Verfahren zur behandlung einer durch lfa-1 vermittelten störung

Info

Publication number
ATE161192T1
ATE161192T1 AT93920241T AT93920241T ATE161192T1 AT E161192 T1 ATE161192 T1 AT E161192T1 AT 93920241 T AT93920241 T AT 93920241T AT 93920241 T AT93920241 T AT 93920241T AT E161192 T1 ATE161192 T1 AT E161192T1
Authority
AT
Austria
Prior art keywords
lfa
treating
antibody
disorder mediated
effective amount
Prior art date
Application number
AT93920241T
Other languages
English (en)
Inventor
Paula M Jardieu
Bruce Montgomery
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE161192T1 publication Critical patent/ATE161192T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Processing Of Solid Wastes (AREA)
AT93920241T 1992-08-21 1993-08-20 Verfahren zur behandlung einer durch lfa-1 vermittelten störung ATE161192T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93326992A 1992-08-21 1992-08-21

Publications (1)

Publication Number Publication Date
ATE161192T1 true ATE161192T1 (de) 1998-01-15

Family

ID=25463656

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93920241T ATE161192T1 (de) 1992-08-21 1993-08-20 Verfahren zur behandlung einer durch lfa-1 vermittelten störung

Country Status (14)

Country Link
US (4) US5622700A (de)
EP (1) EP0656789B1 (de)
JP (1) JPH08500826A (de)
AT (1) ATE161192T1 (de)
AU (1) AU687755B2 (de)
CA (1) CA2140933A1 (de)
DE (1) DE69315847T2 (de)
DK (1) DK0656789T3 (de)
ES (1) ES2112431T3 (de)
GR (1) GR3026344T3 (de)
IL (1) IL106756A (de)
MX (1) MX9305070A (de)
WO (1) WO1994004188A1 (de)
ZA (1) ZA936128B (de)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE161192T1 (de) * 1992-08-21 1998-01-15 Genentech Inc Verfahren zur behandlung einer durch lfa-1 vermittelten störung
FR2700471B1 (fr) * 1993-01-21 1995-04-07 Pasteur Merieux Serums Vacc Utilisation d'anticorps monoclonaux anti-LFA-1 pour la préparation d'un médicament destiné à prévenir le rejet des greffes d'organes solides et médicaments obtenus.
US6884590B1 (en) 1994-02-11 2005-04-26 Cedars-Sinai Medical Center Methods of screening for ulcerative colitis and crohn's disease
US5681699A (en) * 1994-02-11 1997-10-28 Cedars-Sinai Medical Center Methods of diagnosing ulcerative colitis and Crohn's disease
US6576236B1 (en) * 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US20020127201A1 (en) * 1994-07-01 2002-09-12 Dana-Farber Cancer Institute. Methods for inhibiting T cell responses by manipulating a common cytokine receptor gamma-chain
WO1996039187A1 (en) * 1995-06-06 1996-12-12 Allen D Allen Method for treating molluscum contagiosum resulting from hiv infection
US20040197326A1 (en) * 1995-07-27 2004-10-07 Genentech, Inc. Method for treatment of allergic asthma
US5914112A (en) * 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
EP0896542A1 (de) * 1996-03-29 1999-02-17 Universite Laval Verfahren zur wiederherstellung eines funktionellen proteins in einem gewebe durch zelltransplantation
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US7122636B1 (en) * 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
FR2763072B1 (fr) * 1997-05-12 1999-11-05 Pasteur Merieux Serums Vacc Utilisation d'un anticorps monoclonal anti-lfa1 en transplantation renale
EE9900528A (et) * 1997-05-17 2000-06-15 Biogen, Incorporated CD40:CD154 seostumise katkestaja kasutamine adaptiivsete immuunvastuste, eriti transplantaadi hülgamise takistamiseks
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
WO2000029431A1 (en) * 1998-11-17 2000-05-25 Tanox, Inc. Bispecific molecules cross-linking itim and itam for therapy
US6867203B2 (en) 1998-12-29 2005-03-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
WO2000056363A1 (en) 1999-03-19 2000-09-28 Genentech, Inc. Treatment of lfa-1 associated disorders with increasing doses of lfa-1 antagonist
NZ519222A (en) * 1999-12-14 2004-04-30 Genentech Inc TNF-alpha antagonists and LFA-1 antagonist for treating LFA-1 or TNF-alpha mediated disorder
AU2001230920A1 (en) * 2000-01-14 2001-07-24 Genentech Inc. Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1
WO2001070266A2 (en) 2000-03-17 2001-09-27 Millennium Pharmaceuticals, Inc. Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2
AU2001287000A1 (en) 2000-09-01 2002-03-13 The Center For Blood Research, Inc. Modified polypeptides stabilized in a desired conformation and methods for producing same
EP2270187A3 (de) 2001-06-22 2011-08-31 Pioneer Hi-Bred International, Inc. Defensinpolynucleotide und Verfahren zu ihrer Verwendung
AU2003210802B2 (en) 2002-02-05 2009-09-10 Genentech Inc. Protein purification
JP4319979B2 (ja) * 2002-04-26 2009-08-26 ジェネンテック・インコーポレーテッド タンパク質の非アフィニティ精製
EP1592777A4 (de) 2003-02-01 2008-06-04 Tanox Inc Verfahren zur erzeugung hochaffiner antikörper
US7834147B2 (en) 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
EP3095793B1 (de) 2003-07-28 2020-03-25 Genentech, Inc. Verringerung des protein-a-auslaugens während einer affinitätschromatografie
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
EP1682537B1 (de) 2003-11-05 2012-03-28 SARcode Bioscience Inc. Modulatoren der zellulären adhäsion
EP2264191A1 (de) 2003-11-21 2010-12-22 ANP Technologies, Inc. Asymmetrisch verzweigte Polymerkonjugate und Mikroarray-Tests
AU2005244751A1 (en) * 2004-04-16 2005-12-01 Genentech, Inc. Method for augmenting B cell depletion
EP1756163A2 (de) * 2004-06-09 2007-02-28 Genentech, Inc. Verfahren zur behandlung von granuloma annulare oder sarkoid
US7655229B2 (en) * 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
ZA200701783B (en) * 2004-09-02 2009-10-28 Genentech Inc Anti-Fc-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) * 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DE102004059357B8 (de) * 2004-12-03 2009-12-03 Universität Leipzig Antikörper, welcher die Interaktion von humanem Thy-1 und dessen Liganden blockiert, sowie dessen Verwendung
EP2208998A3 (de) 2005-05-02 2011-03-16 ANP Technologies, Inc. Polymerkonjugat-verbesserte Bioassays
CN101175488B (zh) 2005-05-17 2012-04-18 萨可德公司 治疗眼病的组合物和方法
AU2007227609A1 (en) * 2006-03-16 2007-09-27 Genentech, Inc. Methods of treating lupus using CD4 antibodies
US20080279848A1 (en) * 2006-03-16 2008-11-13 Genentech, Inc. Methods of treating lupus using CD4 antibodies
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
AU2007275654A1 (en) 2006-07-19 2008-01-24 The Trustees Of The University Of Pennsylvania WSX-1/p28 as a target for anti-inflammatory responses
AU2007313685C1 (en) 2006-11-02 2015-09-17 Genentech, Inc. Humanized anti-Factor D antibodies
US8569464B2 (en) * 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) * 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
WO2008079302A2 (en) * 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
BRPI0806367A2 (pt) 2007-01-22 2011-09-06 Genentech Inc métodos de purificação de anticorpos
EP1995309A1 (de) * 2007-05-21 2008-11-26 Vivalis Rekombinante Proteinproduktion in EBx -Vogelzellen
HUE046992T2 (hu) 2007-07-09 2020-04-28 Genentech Inc Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során
EP3167886B1 (de) * 2007-10-19 2020-08-05 Novartis AG Zusammensetzungen und verfahren zur behandlung von makulaödem
US20090148435A1 (en) 2007-10-30 2009-06-11 Genentech, Inc. Antibody purification by cation exchange chromatography
EP3632444A3 (de) 2008-04-15 2020-08-26 SARcode Bioscience Inc. Topische lfa-1-antagonisten zur verwendung in der lokalen behandlung von immunerkrankungen
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
US20090258069A1 (en) * 2008-04-15 2009-10-15 John Burnier Delivery of LFA-1 antagonists to the gastrointestinal system
JP2011518155A (ja) * 2008-04-15 2011-06-23 サーコード コーポレイション 免疫関連障害の局所治療に使用するためのエアゾール化ｌｆａ−１アンタゴニスト
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
US8999702B2 (en) * 2008-06-11 2015-04-07 Emd Millipore Corporation Stirred tank bioreactor
US20100021460A1 (en) * 2008-07-15 2010-01-28 Genentech, Inc. Methods of Treating Autoimmune Diseases Using CD4 Antibodies
DK2848625T3 (da) 2008-08-14 2019-10-07 Genentech Inc Fremgangsmåder til fjernelse af en kontaminant under anvendelse af ion bytningsmembrankromatografi med forskydning af naturligt forekommende proteiner
CN103599541A (zh) 2008-09-10 2014-02-26 弗·哈夫曼-拉罗切有限公司 用于防止蛋白质氧化降解的组合物和方法
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
US20110020327A1 (en) * 2008-12-16 2011-01-27 Millipore Corporation Purification of proteins
SG171446A1 (en) 2008-12-16 2011-07-28 Millipore Corp Stirred tank reactor and method
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
WO2010099273A1 (en) 2009-02-27 2010-09-02 Genentech, Inc. Methods and compositions for protein labelling
SI2464725T2 (sl) 2009-08-11 2025-06-30 F. Hoffmann-La Roche Ag Proizvodnja beljakovin v medijih za celične kulture brez glutamina
CN102686738A (zh) 2009-09-01 2012-09-19 弗·哈夫曼-拉罗切有限公司 通过改进的a蛋白洗脱增强的蛋白质纯化
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
EP2531592A1 (de) 2010-02-04 2012-12-12 Vivalis Fed-batch-verfahren mit konzentriertem zellkulturmedium zur effizienten produktion von biologischen wirkstoffen bei eb66-zellen
RU2584232C2 (ru) 2010-03-22 2016-05-20 Дженентек, Инк. Композиции и способы, используемые для стабилизации белоксодержащих готовых форм
SG183947A1 (en) 2010-03-31 2012-10-30 Boehringer Ingelheim Int Anti-cd40 antibodies
EP3372617B1 (de) 2010-04-02 2024-07-24 Amunix Pharmaceuticals, Inc. Bindungsfusionsproteine, bindungsfusionsproteinarzneimittelkonjugate, xten-arzneimittelkonjugate sowie verfahren zur herstellung und verwendung davon
RU2012151500A (ru) 2010-05-03 2014-06-10 Дженентек, Инк. Композиции и способы, пригодные для снижения вязкости белковосодержащих составов
CN107312062B (zh) 2010-05-17 2021-03-16 Emd密理博公司 用于纯化生物分子的刺激响应性聚合物
KR20190067277A (ko) 2010-05-28 2019-06-14 제넨테크, 인크. 락테이트 데히드로게나제 및 피루베이트 데히드로게나제 키나제의 발현의 하향조절에 의한 락테이트 수준의 감소 및 폴리펩티드 생산의 증가
PL3586826T3 (pl) 2010-06-24 2021-10-25 F. Hoffmann-La Roche Ag Kompozycje i sposoby stabilizowania preparatów zawierających białka
JP2013537539A (ja) 2010-08-13 2013-10-03 ジェネンテック， インコーポレイテッド 疾患の治療のためのＩＬ−１β及びＩＬ−１８に対する抗体
WO2012027209A2 (en) 2010-08-23 2012-03-01 Pioneer Hi-Bred International, Inc. Novel defensin variants and methods of use
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
PE20141162A1 (es) 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
CN103429267B (zh) 2011-01-09 2016-05-04 Anp科技公司 疏水分子诱导的支化聚合物集合体及其用途
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
BR112013029893A2 (pt) 2011-05-21 2017-05-30 Macrogenics Inc molécula de ligação a cd3, anticorpo de ligação a cd3, diacorpo de ligação a cd3 e composição farmacêutica
KR102157227B1 (ko) 2011-07-08 2020-09-17 이엠디 밀리포어 코포레이션 일회용 생명공학적 공정용의 개선된 심층 필터
SG11201402283PA (en) 2011-11-16 2014-06-27 Boehringer Ingelheim Int Anti il-36r antibodies
HRP20181846T1 (hr) 2011-12-22 2018-12-28 Genentech, Inc. Kromatografija membranom za ionsku izmjenu
CA2866753C (en) 2012-03-27 2020-09-22 Genentech, Inc. Improved harvest operations for recombinant proteins
KR102124758B1 (ko) 2012-05-03 2020-06-19 베링거 인겔하임 인터내셔날 게엠베하 항-ｉｌ-23ｐ19 항체
CA2873646C (en) 2012-05-18 2022-04-26 Genentech, Inc. High-concentration monoclonal antibody formulations
HK1210782A1 (en) 2012-07-25 2016-05-06 Sarcode Bioscience Inc. Lfa-1 inhibitor and polymorph thereof
EP2919759A4 (de) 2012-11-14 2016-07-20 Ohio State Innovation Foundation Materialien und methoden zur behandlung von glioblastomen
WO2014100095A1 (en) 2012-12-19 2014-06-26 Genentech, Inc. Methods and compositions for radiohalogen protein labeling
CA2900219C (en) 2013-02-05 2019-06-18 Anp Technologies, Inc. Nanoparticles containing a taxane and their use
JO3529B1 (ar) * 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
US10633449B2 (en) 2013-03-27 2020-04-28 Cedars-Sinai Medical Center Treatment and reversal of fibrosis and inflammation by inhibition of the TL1A-DR3 signaling pathway
EP3022295A4 (de) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signatur des tl1a (tnfsf15)-signalweges
MX2016001854A (es) 2013-08-12 2016-09-06 Genentech Inc Composiciones y metodo para tratar condiciones asociadas con el complemento.
US9840543B2 (en) 2014-01-31 2017-12-12 Boehringer Ingelheim International Gmbh Anti-BAFF antibodies
EA201692109A1 (ru) 2014-05-01 2017-03-31 Дженентек, Инк. Варианты антител к фактору d и их применение
HRP20201663T1 (hr) 2014-07-09 2020-12-25 F. Hoffmann - La Roche Ag PRILAGOĐAVANJE pH VRIJEDNOSTI RADI POBOLJŠANJA OPORAVKA BANAKA STANICA USLIJED ODMRZAVANJA
WO2016014775A1 (en) 2014-07-24 2016-01-28 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of il-23a related diseases
SG11201705728RA (en) 2015-02-04 2017-08-30 Boehringer Ingelheim Int Methods of treating inflammatory diseases
EP3344655B1 (de) 2015-09-01 2023-07-26 Boehringer Ingelheim International GmbH Verwendung von anti-cd40-antikörpern zur behandlung von lupus nephritis
SI3307322T1 (sl) 2015-09-04 2021-08-31 Primatope Therapeutics Inc. Humanizirana protitelesa proti CD40 in njihove uporabe
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
JP2018536650A (ja) 2015-10-30 2018-12-13 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体コンジュゲート及びその使用
WO2017161342A1 (en) 2016-03-17 2017-09-21 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through rnaset2
WO2017172994A1 (en) 2016-03-29 2017-10-05 Geltor, Inc. Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
CA3044686A1 (en) 2016-12-22 2018-06-28 Genentech, Inc. Methods and formulations for reducing reconstitution time of lyophilized polypeptides
EP3601350A1 (de) 2017-03-27 2020-02-05 Boehringer Ingelheim International GmbH Kombinationstherapie gegen il-36r-antikörper
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
BR112020024078A2 (pt) 2018-06-29 2021-02-17 Boehringer Ingelheim International Gmbh anticorpos anti-cd40 para uso no tratamento de doença autoimune
JP7419273B2 (ja) 2018-07-03 2024-01-22 ブリストル－マイヤーズ スクイブ カンパニー 組換えタンパク質を製造する方法
MA53859A (fr) 2018-10-10 2022-01-19 Boehringer Ingelheim Int Procédé de transfert de gaz de membrane dans une culture de bioréacteur à haute densité
MX2021010783A (es) 2019-03-08 2021-09-30 Boehringer Ingelheim Int Formulaciones de anticuerpo anti-il-36r.
WO2020205716A1 (en) 2019-04-01 2020-10-08 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
WO2020210440A1 (en) 2019-04-12 2020-10-15 Geltor, Inc. Recombinant elastin and production thereof
WO2021021973A1 (en) 2019-08-01 2021-02-04 Bristol-Myers Squibb Company Methods of improving protein productivity in fed-batch cell cultures
PE20230414A1 (es) 2020-03-24 2023-03-07 Genentech Inc Agentes de fijacion a tie2 y metodos de uso
EP4213939A1 (de) 2020-09-21 2023-07-26 Boehringer Ingelheim International GmbH Verwendung von anti-cd40-antikörpern zur behandlung von entzündlichen erkrankungen
EP4217383A1 (de) 2020-09-22 2023-08-02 Bristol-Myers Squibb Company Verfahren zur herstellung therapeutischer proteine
US20240317868A1 (en) 2021-02-05 2024-09-26 Boehringer Ingelheim International Gmbh Anti-il1rap antibodies
WO2023015234A1 (en) 2021-08-05 2023-02-09 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
WO2023049687A1 (en) 2021-09-21 2023-03-30 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292636A (en) * 1986-03-31 1994-03-08 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using soluble T cell surface molecules
US5762933A (en) * 1987-01-05 1998-06-09 Institut National De La Sante Et De La Recherche Medicale Method for preventing and treating graft failure in a human patient using a monoclonal antibody specific for leucocyte functional antigen LFA-1
EP0303692A4 (en) * 1987-02-26 1990-12-05 Dana Farber Cancer Institute Cloning of lfa-1
US5284931A (en) * 1987-05-04 1994-02-08 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
ES2080044T3 (es) * 1987-05-04 1996-02-01 Dana Farber Cancer Inst Inc Moleculas de adhesion intercelular y sus ligandos de fijacion.
US5538724A (en) * 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
US5403919A (en) * 1987-08-11 1995-04-04 Board Of Trustees Of The Leland Stanford Junior University Stanford University Method to control leukocyte extravasation
US4797277A (en) * 1987-09-22 1989-01-10 Pharmacia Ab Method for reperfusion therapy
DE3852374T2 (de) * 1987-11-02 1995-05-04 Baylor College Medicine Verwendung von ICAM-1 oder ihre funktionelle Derivate zur Behandlung unspezifischer Entzündungen.
US5002869A (en) * 1987-11-02 1991-03-26 Dana-Farber Cancer Institute Monoclonal antibody specific to a novel epitope of the LFA-1 antigen of human T lymphocytes
US5395929A (en) * 1987-12-15 1995-03-07 Dana Farber Cancer Institute Isolated nucleic acid encoding the alpha subunit of the human leukocyte adhesion receptor
US5071964A (en) * 1988-05-04 1991-12-10 Dana-Farber Cancer Institute, Inc. Protein micelles
US5147637A (en) * 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
WO1990008187A1 (en) * 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
US5235049A (en) * 1989-01-24 1993-08-10 Molecular Therapeutics, Inc. Nucleic acid sequences encoding a soluble molecule (SICAM-1) related to but distinct from ICAM-1
NO900155L (no) * 1989-01-24 1990-07-25 Molecular Therapeutics Inc Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1.
CA2008368C (en) * 1989-01-24 2003-04-08 Jeffrey Greve Soluble molecule related to but distinct from icam-1
NZ245651A (en) * 1989-03-09 1997-06-24 Blood Res Center Ligand molecules (e.g. antibodies and fragments) capable of binding to intercellular adhesion molecule-2 (icam-2) and their use
EP0462184A4 (en) * 1989-03-09 1992-01-08 Dana Farber Cancer Institute Method of treating viral infections using lfa-1
GB8912497D0 (en) * 1989-05-31 1989-07-19 Cobbold Stephen P Monoclonal antibodies
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
WO1990015076A2 (en) * 1989-06-02 1990-12-13 The Johns Hopkins University School Of Medicine MONOCLONAL ANTIBODIES AGAINST LEUKOCYTE ADHESION RECEPTOR β-CHAIN, METHODS OF PRODUCING THESE ANTIBODIES AND USE THEREFORE
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
GB9009549D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method
WO1991018011A1 (en) * 1990-05-15 1991-11-28 Swinburne Limited Inhibition of cell adhesion using intercellular adhesion molecule-1-like peptides and/or analogues thereof
AU8631991A (en) * 1990-08-27 1992-03-17 Cetus Corporation Cd18 peptide medicaments for the treatment of disease
JPH06501931A (ja) * 1990-08-31 1994-03-03 ベーリンガー・インゲルハイム・ファーマシュウティカルズ・インコーポレイテッド 抗接着性抗体を用いるエンドトキシンショックの治療法
CA2103059C (en) * 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
EP0610298A1 (de) * 1991-10-01 1994-08-17 The General Hospital Corporation Verhinderung der Abstossung eines Wirt-Transplantats durch Verwendung von gegen Adhäsionsmolekülen gebildeten Antikörpern
US5854070A (en) * 1992-07-16 1998-12-29 Icos Corporation Murine and humanizer 23F2G antibodies and cell lines expressing said antibodies
JPH06511156A (ja) * 1992-07-16 1994-12-15 イコス　コーポレイション 炎症性疾患状態に関連する症状の緩和
ATE161192T1 (de) * 1992-08-21 1998-01-15 Genentech Inc Verfahren zur behandlung einer durch lfa-1 vermittelten störung

Also Published As

Publication number Publication date
IL106756A (en) 2006-07-05
WO1994004188A1 (en) 1994-03-03
ZA936128B (en) 1995-02-20
US20040120960A1 (en) 2004-06-24
GR3026344T3 (en) 1998-06-30
DE69315847T2 (de) 1998-06-25
US5622700A (en) 1997-04-22
EP0656789A1 (de) 1995-06-14
EP0656789B1 (de) 1997-12-17
US20050281817A1 (en) 2005-12-22
MX9305070A (es) 1994-04-29
AU687755B2 (en) 1998-03-05
DE69315847D1 (de) 1998-01-29
CA2140933A1 (en) 1994-02-22
AU5083693A (en) 1994-03-15
JPH08500826A (ja) 1996-01-30
ES2112431T3 (es) 1998-04-01
US20020197248A1 (en) 2002-12-26
IL106756A0 (en) 1993-12-08
DK0656789T3 (da) 1998-08-24

Similar Documents

Publication Publication Date Title
ATE161192T1 (de) Verfahren zur behandlung einer durch lfa-1 vermittelten störung
ATE338563T1 (de) Verfahren zur behandlung von patienten die unter multipler sklerose leiden mit konsensus- interferon
DE69736712D1 (de) Verfahren zur milderung von neuropatischen schmerz mit prosaposin verwandten peptiden
DE69318835D1 (de) Behandlung einer refluxstörung durch injektion von mikropartikeln
DE69334035D1 (de) Verfahren zur vorbeugung von nmda-rezeptor vermittelten neuronalen schäden
DE69433079D1 (de) Verwendung von imidazole zur behandlung von krankheiten, die durch neovaskularisierung gekennzeichnet sind
DE69229275D1 (de) Herstellung eines arzneimittels zur behandlung von augenentzündung durch blockierung von zelladhäsionsmolekulen
ATE196849T1 (de) Verfahren zur behandlung von multiplesklerose
DE69325393D1 (de) Pharmazeutische zusammensetzungen und verfahren unter verwendung von isobutyramid zur behandlung von betaglobinerkrankungen
DK0863760T3 (da) Anvendelse af forbindelser med antimineralcorticoid virkning over for narkotikafvænning
NZ337073A (en) use of an anti CD40L compound to treat a patient with an autoimmune disease or chronic immune system disorder
ATE73350T1 (de) Verfahren zur tierischen wachstumsfoerderung.
MA22915A1 (fr) Methodes de traitement de l'osteoporose pour utilisation de faibles doses de phosphonates.
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
ZA947783B (en) Method of treating depressed reticuloendothelial system function
DE69327248D1 (de) Verfahren zur behandlung des symptomenkomplexes des prämenstruellen syndroms mit vitamin d oder vitamin d und calcium
ATE308994T1 (de) Gebrauch von antikörpern zur verhinderung von auswirkungen hervorgerufen durch grampositive- und myko-bakterien
ATE100331T1 (de) Verfahren zur behandlung von septischem schock.
ATE202935T1 (de) Verfahren zur behandlung von haarausfall
MY104521A (en) Treatment of depression.
OA07142A (fr) Procédé et dispositif pour élaborer et délivrer le montant de taxes téléphoniques.
ATE17007T1 (de) Neue o-alkyl-o-carbamoyl-glycero-phosphocholine und verfahren zu ihrer herstellung.
DE69231628D1 (de) Erweichende zusammensetzung
ATE149840T1 (de) Behandlung von leberkrebs
DE3578135D1 (de) Behandlung eines ultrafiltrats durch elektrodialyse.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee